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Public health interventions are usually implemented without any attempt to prospectively 
evaluate them with an experimental 
research design. Thus the only 
way to evaluate the outcome of 
the intervention is to describe 
what happened before and after 
its implementation. In a new study 
published in PLoS Medicine, Morgan 
et al. have examined the change in 
deaths attributed to paracetamol 
(acetaminophen) poisoning in 
England and Wales in the six years 
before and after a legislated reduction 
in the maximum pack size [1]. The 
average number of deaths preceding 
the regulation was 212/year and 
afterwards it fell to an average of 
154/year (see Figure 1 and Table 1 
in [1]). Therefore, readers could be 
forgiven for being puzzled that the 
authors have declared that they found 
little evidence to suggest that the 
regulations caused the reduction.
The authors did show statistically 
signiﬁ cant changes in deaths 
attributed to paracetamol poisoning 
after the legislation compared to 
the preceding six years before the 
legislation (Table 2 in [1]). But they 
also assessed whether the observed 
changes over time were unique to 
paracetamol. They compared the 
changes against the number of 
poisoning deaths involving compound 
paracetamol (not covered by the 
regulations), aspirin, antidepressants, 
and against the number of non-
poisoning suicide deaths, over the 
same time period. It is the lack of 
statistically signiﬁ cant and consistent 
changes in the relative rates of deaths 
for paracetamol versus coincidental 
changes for other drugs (Table 4 in 
[1]) that lead the authors to conclude 
that the regulations may have had no 
effect. 
Was the Conclusion Justiﬁ ed?
The changes seen with each of the 
comparator drugs in this study might 
each have an explanation that would 
cast the regulatory effect in a more 
favourable light. 
For a start, the regulations also 
applied to aspirin—so it is hardly 
surprising that a similar reduction 
was noted for aspirin fatalities at the 
same time. Indeed the reductions in 
death from both paracetamol and from 
aspirin could be considered as further 
evidence of the effectiveness of the 
regulations. 
Second, it is likely that some deaths 
attributed to paracetamol compounds 
are deaths where there has also 
been substantial co-ingestion of non-
compound paracetamol, since people 
commonly ingest more than one 
medication in overdose. Deaths in 
these circumstances due to paracetamol 
hepatotoxicity may still be classiﬁ ed as 
due to paracetamol compound, so the 
reduction in paracetamol compound 
deaths may, in part, have resulted 
from the legislation [2]. Conversely, 
deaths due to the other components 
of compound preparations may 
be misclassiﬁ ed as deaths due to 
paracetamol. While coronial records 
may have improved, 25 years ago over 
a quarter of deaths classiﬁ ed as due to 
paracetamol were on review found to 
be due to paracetamol/propoxyphene 
combinations [2]. The rate of these 
deaths obviously cannot be modiﬁ ed by 
regulating paracetamol. 
Third, the changes in deaths from 
antidepressant overdose seem likely 
to reﬂ ect changes in antidepressant 
prescribing over the last decade [3]. An 
important trend in such prescribing is 
the increasing use of selective serotonin 
reuptake inhibitors and other new 
agents that are less toxic in overdose 
than older antidepressants [4], 
particularly for new patients and others 
at higher risk of suicide. 
Finally, changes in overall suicide 
rates may reﬂ ect reductions in 
carbon monoxide poisoning due 
to the introduction of catalytic 
converters in cars [5]. So while 
Morgan and colleagues’ new study 
raises the possibility that the changes 
in paracetamol poisoning deaths 
over time may be unrelated to the 
legislation, and may in fact be due to 
other more general changes in suicidal 
behaviour, the argument is far from 
conclusive. 
All the changes in suicide rate 
shown in Figure 1 in [1] could be 
reinterpreted to reﬂ ect the effects of 
reductions in the lethality of particular 
modes of suicide, rather than being 
an indication of the ineffectiveness of 
legislation on pack size. Historically, 
the most dramatic reductions in 
suicide rates have reﬂ ected changes 
in lethality of method rather than a 
reduction in attempts. One oft-quoted 
example is the 80%–87% fall in gas-
poisoning deaths between 1963 and 
1971 in England and Wales with the 
replacement of coal gas with natural 
gas [6]. Even more impressive is the 
halving of total suicide rates in Sri 
Lanka over ten years coinciding with 
the banning of a small number of 
highly lethal pesticides (Gunnell et al., 
unpublished data). 
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Frequentist statistics, as used by 
Morgan et al., test whether a null 
hypothesis can be rejected from the 
data in the study. The researchers have 
not proven there was no effect from the 
legislation; they simply were unable to 
conﬁ dently reject the possibility that 
this difference over the next six years 
was simply due to chance. 
Other Studies on Drug Packaging 
and Self Harm
Morgan and colleagues’ study should 
not be examined in isolation. While 
the effect of safety packaging in 
reducing lethal childhood poisoning 
is established, there have been only a 
few other instances where the effect 
of such regulatory changes on adult 
poisoning have been evaluated [7,8]. 
However, many researchers have taken 
the opportunity to look at the effect of 
restrictions on paracetamol pack size 
[9–19]. These studies have generally 
shown small but favourable effects—
in some cases reaching statistical 
signiﬁ cance and sometimes not. Two 
studies from Scotland showed no 
change whatsoever [9,10]. 
It seems most likely that the pack 
size regulations did change the pattern 
of paracetamol poisoning but that 
changes were far more modest than 
hoped. Ingestion of eight grams of 
paracetamol (the maximum amount 
allowed in a pack from non-pharmacy 
retail outlets) should rarely lead to 
toxicity and ingestion of 16 grams of 
paracetamol (the maximum pack size 
available from pharmacies) should 
rarely lead to death. So the reasons for 
the very modest reduction in deaths 
found in these studies may be due to 
failures in implementation rather than 
any inherent ﬂ aw in the concept. A 
study in London three years after the 
regulations were introduced found 
that 46% of people presenting with 
overdose had purchased potentially 
toxic amounts of paracetamol in a 
manner contravening the spirit of the 
1998 legislation and the Medicines 
and Healthcare Products Regulatory 
Agency’s recommended voluntary 
restraints on multiple packet sales [20]. 
Implications for Drug Regulators
What is the lesson for regulators in 
the UK and elsewhere from these 
studies on paracetamol regulation in 
the UK? We think they provide some 
further evidence that changes in drug 
availability and packaging can lead to 
reductions in deaths from self harm. 
However, the changes may be much 
less than anticipated if they cannot be 
enforced. 
Morgan et al.’s study also indicates 
the beneﬁ ts of having national 
databases on deaths from poisoning. 
These databases could be further 
strengthened by having more 
information routinely collected and 
regularly audited for accuracy. At the 
moment such databases are more than 
adequate for determining priorities 
for public health interventions but 
less than ideal for evaluating these 
same interventions. We would heartily 
endorse the authors’ proposal to 
ensure that prospective evaluation is 
an integral part of such public health 
interventions [12]. When this happens, 
we will know that evidence-based public 
health is more than just a slogan. 
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